vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Simpson Manufacturing Co., Inc. (SSD). Click either name above to swap in a different company.
Simpson Manufacturing Co., Inc. is the larger business by last-quarter revenue ($588.0M vs $339.0M, roughly 1.7× HAEMONETICS CORP). Simpson Manufacturing Co., Inc. runs the higher net margin — 15.0% vs 13.2%, a 1.8% gap on every dollar of revenue. On growth, Simpson Manufacturing Co., Inc. posted the faster year-over-year revenue change (9.1% vs -2.7%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -0.8%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Simpson Manufacturing Company is a leading building materials manufacturer in the United States that produces structural connectors, fasteners, anchors, and products for new construction and retrofitting.
HAE vs SSD — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $588.0M |
| Net Profit | $44.7M | $88.2M |
| Gross Margin | 59.7% | 45.2% |
| Operating Margin | 19.9% | 19.5% |
| Net Margin | 13.2% | 15.0% |
| Revenue YoY | -2.7% | 9.1% |
| Net Profit YoY | 19.3% | 13.3% |
| EPS (diluted) | $0.95 | $2.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $588.0M | ||
| Q4 25 | $339.0M | $539.3M | ||
| Q3 25 | $327.3M | $623.5M | ||
| Q2 25 | $321.4M | $631.1M | ||
| Q1 25 | $330.6M | $538.9M | ||
| Q4 24 | $348.5M | $517.4M | ||
| Q3 24 | $345.5M | $587.2M | ||
| Q2 24 | $336.2M | $597.0M |
| Q1 26 | — | $88.2M | ||
| Q4 25 | $44.7M | $56.2M | ||
| Q3 25 | $38.7M | $107.4M | ||
| Q2 25 | $34.0M | $103.5M | ||
| Q1 25 | $58.0M | $77.9M | ||
| Q4 24 | $37.5M | $55.4M | ||
| Q3 24 | $33.8M | $93.5M | ||
| Q2 24 | $38.4M | $97.8M |
| Q1 26 | — | 45.2% | ||
| Q4 25 | 59.7% | 43.4% | ||
| Q3 25 | 59.5% | 46.4% | ||
| Q2 25 | 59.8% | 46.7% | ||
| Q1 25 | 58.4% | 46.8% | ||
| Q4 24 | 55.5% | 44.0% | ||
| Q3 24 | 54.2% | 46.8% | ||
| Q2 24 | 52.0% | 46.7% |
| Q1 26 | — | 19.5% | ||
| Q4 25 | 19.9% | 13.9% | ||
| Q3 25 | 17.9% | 22.6% | ||
| Q2 25 | 16.8% | 22.2% | ||
| Q1 25 | 21.6% | 19.0% | ||
| Q4 24 | 16.9% | 14.8% | ||
| Q3 24 | 15.0% | 21.3% | ||
| Q2 24 | 11.8% | 22.1% |
| Q1 26 | — | 15.0% | ||
| Q4 25 | 13.2% | 10.4% | ||
| Q3 25 | 11.8% | 17.2% | ||
| Q2 25 | 10.6% | 16.4% | ||
| Q1 25 | 17.5% | 14.5% | ||
| Q4 24 | 10.8% | 10.7% | ||
| Q3 24 | 9.8% | 15.9% | ||
| Q2 24 | 11.4% | 16.4% |
| Q1 26 | — | $2.13 | ||
| Q4 25 | $0.95 | $1.34 | ||
| Q3 25 | $0.81 | $2.58 | ||
| Q2 25 | $0.70 | $2.47 | ||
| Q1 25 | $1.17 | $1.85 | ||
| Q4 24 | $0.74 | $1.31 | ||
| Q3 24 | $0.66 | $2.21 | ||
| Q2 24 | $0.74 | $2.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $341.0M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $2.1B |
| Total Assets | $2.5B | $3.0B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $341.0M | ||
| Q4 25 | $363.4M | $384.1M | ||
| Q3 25 | $296.4M | $297.3M | ||
| Q2 25 | $292.9M | $190.4M | ||
| Q1 25 | $306.8M | $150.3M | ||
| Q4 24 | $320.8M | $239.4M | ||
| Q3 24 | $299.3M | $339.4M | ||
| Q2 24 | $344.4M | $354.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $300.0M | ||
| Q3 25 | $1.2B | $371.3M | ||
| Q2 25 | $1.2B | $376.9M | ||
| Q1 25 | $1.2B | $382.5M | ||
| Q4 24 | — | $388.1M | ||
| Q3 24 | — | $393.8M | ||
| Q2 24 | — | $399.4M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $911.5M | $2.0B | ||
| Q3 25 | $849.2M | $2.0B | ||
| Q2 25 | $882.3M | $1.9B | ||
| Q1 25 | $820.8M | $1.9B | ||
| Q4 24 | $906.9M | $1.8B | ||
| Q3 24 | $878.9M | $1.9B | ||
| Q2 24 | $905.4M | $1.8B |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $2.5B | $3.1B | ||
| Q3 25 | $2.4B | $3.0B | ||
| Q2 25 | $2.5B | $3.0B | ||
| Q1 25 | $2.5B | $2.8B | ||
| Q4 24 | $2.5B | $2.7B | ||
| Q3 24 | $2.5B | $2.9B | ||
| Q2 24 | $2.5B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | 0.15× | ||
| Q3 25 | 1.44× | 0.19× | ||
| Q2 25 | 1.39× | 0.20× | ||
| Q1 25 | 1.49× | 0.21× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.23× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | — |
| Free Cash FlowOCF − Capex | $87.2M | — |
| FCF MarginFCF / Revenue | 25.7% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $93.6M | $155.7M | ||
| Q3 25 | $111.3M | $170.2M | ||
| Q2 25 | $17.4M | $125.2M | ||
| Q1 25 | $116.6M | $7.6M | ||
| Q4 24 | $43.8M | $115.8M | ||
| Q3 24 | $48.8M | $103.3M | ||
| Q2 24 | $-27.4M | $111.1M |
| Q1 26 | — | — | ||
| Q4 25 | $87.2M | $119.0M | ||
| Q3 25 | $106.3M | $133.9M | ||
| Q2 25 | $13.6M | $87.3M | ||
| Q1 25 | $100.9M | $-42.6M | ||
| Q4 24 | $35.2M | $60.3M | ||
| Q3 24 | $39.4M | $58.1M | ||
| Q2 24 | $-33.1M | $70.9M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | 22.1% | ||
| Q3 25 | 32.5% | 21.5% | ||
| Q2 25 | 4.2% | 13.8% | ||
| Q1 25 | 30.5% | -7.9% | ||
| Q4 24 | 10.1% | 11.7% | ||
| Q3 24 | 11.4% | 9.9% | ||
| Q2 24 | -9.8% | 11.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 6.8% | ||
| Q3 25 | 1.5% | 5.8% | ||
| Q2 25 | 1.2% | 6.0% | ||
| Q1 25 | 4.7% | 9.3% | ||
| Q4 24 | 2.5% | 10.7% | ||
| Q3 24 | 2.7% | 7.7% | ||
| Q2 24 | 1.7% | 6.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | 2.77× | ||
| Q3 25 | 2.88× | 1.58× | ||
| Q2 25 | 0.51× | 1.21× | ||
| Q1 25 | 2.01× | 0.10× | ||
| Q4 24 | 1.17× | 2.09× | ||
| Q3 24 | 1.44× | 1.10× | ||
| Q2 24 | -0.71× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
SSD
Segment breakdown not available.
